Reslizumab News
Reslizumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Reslizumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for...
- Evidence level: L5
- Predicted indications (20):
- thrombocytopenia due to immune destruction (99.5%)
- primary release disorder of platelets (99.2%)
- pseudo-von Willebrand disease (99.0%)
- autoimmune thrombocytopenic (98.9%)
- Glanzmann thrombasthenia (98.6%)
- neonatal thrombocytopenia (98.1%)
- autosomal thrombocytopenia with normal platelets (98.0%)
- Evans syndrome (97.9%)
- filariasis (96.2%)
- acne keloid (95.3%)
- neonatal dermatomyositis (94.9%)
- dermatitis (94.8%)
- amyopathic dermatomyositis (94.7%)
- acrodermatitis chronica atrophicans (94.3%)
- mixed-type autoimmune hemolytic anemia (94.1%)
- secondary interstitial lung disease specific to childhood associated with a connective tissue disease (94.1%)
- hydroa vacciniforme, familial (94.0%)
- drug-induced autoimmune hemolytic anemia (93.8%)
- syndromic constitutional thrombocytopenia (93.6%)
- neonatal autoimmune hemolytic anemia (92.9%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.